The first trial of stem cells produced from a patient's own body has been approved by the Japanese government - Japan's health minister, Norihisa Tamura, ruled that the cells can now be tested in patients. Researchers in Japan will use the cells to attempt to treat a form of blindness - age-related macular degeneration. The announcement was described as a "major step forward" for research in this field.
There are already clinical trials taking place that use stem cells harvested from embryos, but this is ethically controversial and the cells will not match a patient's own tissues, so there is a risk of rejection. Induced pluripotent stem cells (IPSCs), however, are made by coaxing a sample of the patient's skin to become stem cells, so there should be no risk of rejection.
The trial will be run by the Riken Center for Developmental Biology and the Institute of Biomedical Research and Innovation Hospital in Kobe. Initially, six patients will receive transplants of cells to see if the procedure can restore their damaged vision.
Prof Chris Mason, an expert on regenerative medicine at University College London said: "This was expected, but it's obviously a major step forward. They [IPSCs] are beneficial for two main reasons. One, they are from the patients themselves so the chance of rejection is greatly reduced and there are the ethical considerations - they do not have the baggage which comes with embryonic stem cells." However the downside to IPSCs is that they were discovered much later than embryonic stem cells, so the science is not as advanced and therefore the technology is less safe.
Jack
No comments:
Post a Comment